CN1380883A - 雪花胺的新衍生物和类似物 - Google Patents

雪花胺的新衍生物和类似物 Download PDF

Info

Publication number
CN1380883A
CN1380883A CN01801342A CN01801342A CN1380883A CN 1380883 A CN1380883 A CN 1380883A CN 01801342 A CN01801342 A CN 01801342A CN 01801342 A CN01801342 A CN 01801342A CN 1380883 A CN1380883 A CN 1380883A
Authority
CN
China
Prior art keywords
alkyl
compound
nmr
cdcl
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN01801342A
Other languages
English (en)
Chinese (zh)
Inventor
U·乔迪斯
J·福罗里克
M·特鲁
M·赫恩夏尔
L·斯佐尔纳
B·卡尔兹
S·维尔兹格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanochemia Pharmazeutika AG
Original Assignee
Sanochemia Pharmazeutika AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanochemia Pharmazeutika AG filed Critical Sanochemia Pharmazeutika AG
Publication of CN1380883A publication Critical patent/CN1380883A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/94—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom spiro-condensed with carbocyclic rings or ring systems, e.g. griseofulvins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Furan Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
CN01801342A 2000-03-31 2001-03-22 雪花胺的新衍生物和类似物 Pending CN1380883A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
ATA546/2000 2000-03-31
AT5462000 2000-03-31
AT2382001 2001-02-15
ATA238/2001 2001-02-15

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN 200610054791 Division CN1827621A (zh) 2000-03-31 2001-03-22 雪花胺的新衍生物和类似物

Publications (1)

Publication Number Publication Date
CN1380883A true CN1380883A (zh) 2002-11-20

Family

ID=25608130

Family Applications (1)

Application Number Title Priority Date Filing Date
CN01801342A Pending CN1380883A (zh) 2000-03-31 2001-03-22 雪花胺的新衍生物和类似物

Country Status (26)

Country Link
US (2) US7166588B2 (enExample)
EP (1) EP1181294B1 (enExample)
JP (1) JP2003529602A (enExample)
CN (1) CN1380883A (enExample)
AT (1) ATE263171T1 (enExample)
AU (1) AU785385B2 (enExample)
BG (1) BG65134B1 (enExample)
BR (1) BR0105563A (enExample)
CA (1) CA2368966A1 (enExample)
CZ (1) CZ300160B6 (enExample)
DE (1) DE50101827D1 (enExample)
DK (1) DK1181294T3 (enExample)
ES (1) ES2215885T3 (enExample)
HK (1) HK1049832A1 (enExample)
HU (1) HUP0202233A3 (enExample)
IS (1) IS2287B (enExample)
MX (1) MXPA01012275A (enExample)
NO (1) NO326458B1 (enExample)
NZ (1) NZ516302A (enExample)
PL (1) PL202463B1 (enExample)
PT (1) PT1181294E (enExample)
RU (1) RU2241001C2 (enExample)
SI (1) SI1181294T1 (enExample)
SK (1) SK285909B6 (enExample)
TR (1) TR200400857T4 (enExample)
WO (1) WO2001074820A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116082352A (zh) * 2023-02-16 2023-05-09 西南交通大学 一种加兰他敏衍生物及其制备方法和用途
CN118908968A (zh) * 2024-10-09 2024-11-08 威胜生物医药(苏州)股份有限公司 一种加兰他敏中间体衍生物及其催化氧化制备方法
CN119528922A (zh) * 2024-11-22 2025-02-28 泰安汉威集团有限公司 一种氢溴酸加兰他敏关键杂质-氢溴酸表加兰他敏的手性合成方法

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4721386B2 (ja) * 2001-07-10 2011-07-13 第一三共株式会社 新規ガランタミン類縁体
MXPA04009254A (es) * 2002-03-25 2005-06-08 Sanochemia Pharmazeutika Ag Procedimiento para la obtencion de norgalantamina, derivados de norgalantamina asi como sus isomeros.
AT414125B (de) * 2003-09-29 2006-09-15 Sanochemia Pharmazeutika Ag Neue derivate des 4a,5,9,10,11,12-hexahydro- benzofuro(3a,3,2)(2) benzazepin, verfahren zu deren herstellung sowie deren verwendung zur herstellung von arzneimitteln
AT500143A1 (de) * 2004-04-22 2005-11-15 Sanochemia Pharmazeutika Ag Cholinesterase-inhibitoren in liposomen sowie deren herstellung und verwendung
US7877350B2 (en) * 2005-06-27 2011-01-25 Ab Initio Technology Llc Managing metadata for graph-based computations
DE602006015338D1 (de) * 2005-09-22 2010-08-19 Galantos Pharma Gmbh Cholinerge enhancer mit verbesserter durchgängigkeit durch die blut-hirn-schranke zur behandlung von krankheiten, die mit kognitiven störungen einhergehen
US20090253654A1 (en) 2005-09-22 2009-10-08 Galantos Pharma Gmbh Cholinergic enhancers with improved blood-brain barrier permeability for the treatment of diseases accompanied by cognitive impairment
WO2008022365A2 (de) * 2006-08-24 2008-02-28 Sanochemia Ltd. Mittel zum beeinflussen der wirkungen von organophosphorverbindungen und verwendung von galanthamin, dessen derivaten und analoga zum herstellen solcher mittel
CA2721007C (en) 2008-04-14 2014-04-29 Galantos Pharma Gmbh Derivatives of galantamine as pro-drugs for the treatment of human brain diseases
BG110141A (en) * 2008-05-23 2009-12-31 "Софарма" Ад GALANTAMINE DERIVATIVES, METHODS FOR THEIR PREPARATION AND USE
CN107066241B (zh) 2010-06-15 2021-03-09 起元技术有限责任公司 用于动态加载基于图的计算的系统和方法
WO2013160728A1 (en) 2012-04-26 2013-10-31 Alma Mater Studiorum - Universita' Di Bologna Dual targeting compounds for the treatment of alzheimer's disease
US10108521B2 (en) * 2012-11-16 2018-10-23 Ab Initio Technology Llc Dynamic component performance monitoring
CN106170762B (zh) 2013-12-05 2020-01-14 起元技术有限责任公司 管理包括子图的数据流图所用的接口
SG11201701662XA (en) 2014-09-02 2017-04-27 Ab Initio Technology Llc Visually specifying subsets of components in graph-based programs through user interactions
WO2016036826A1 (en) 2014-09-02 2016-03-10 Ab Initio Technology Llc Compiling graph-based program specifications
US10657134B2 (en) 2015-08-05 2020-05-19 Ab Initio Technology Llc Selecting queries for execution on a stream of real-time data
US12006301B1 (en) 2021-05-13 2024-06-11 Florida A&M University And synthesis of dual 5-HT1A and 5-HT7 receptor ligands

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3947445A (en) * 1974-05-09 1976-03-30 Stanford Research Institute Diazabicyclooctanes and diazabicycloheptanes
US4663318A (en) 1986-01-15 1987-05-05 Bonnie Davis Method of treating Alzheimer's disease
EP0363415B1 (en) 1987-05-04 2008-10-15 Davis, Bonnie Compounds for the treatment of alzheimer's disease
NL8800350A (nl) 1988-02-12 1989-09-01 Stichting Biomedical Research Synthetische galanthamine-derivaten, werkwijze voor het bereiden daarvan, en farmaceutische samenstellingen.
US4954502A (en) 1988-06-10 1990-09-04 Bristol-Myers Squibb Company 1-indolyalkyl-4-(substituted-pyridinyl)piperazines
US5336675A (en) * 1991-05-14 1994-08-09 Ernir Snorrason Method of treating mania in humans
US5153193A (en) * 1991-10-01 1992-10-06 Hoechst-Roussel Pharmaceuticals Incorporated Carbamate derivatives of 4-amino-3-isoxazolidinones, 3-amino-1-hydroxypyrrolidin-2-ones and 1-amino-1-cyclopropanecarboxylic acid analogs
US6323195B1 (en) 1993-10-15 2001-11-27 Aventis Pharmaceuticals Inc. Galanthamine derivatives as acetylcholinesterase inhibitors
US6323196B1 (en) 1993-10-15 2001-11-27 Aventis Pharmaceuticals Inc. Galanthamine derivatives as acetylcholinesterase inhibitors
US5428159A (en) * 1994-04-08 1995-06-27 Ciba-Geigy Corporation Method of manufacture of (-)-galanthamine in high yield and purity substantially free of epigalanthamine
AT401058B (de) 1994-10-21 1996-06-25 Waldheim Pharmazeutika Gmbh Verfahren zum herstellen von derivaten des 4a,5, 9,10,11,12,-hexahydro-6h-benzofuro(3a,-3,2-ef) (2)benzazepins
SK283877B6 (sk) * 1994-10-21 2004-04-06 Sanochemia Pharmazeutika Ag Spôsob výroby derivátov 4a,5,9,10,11,12,-hexahydro-6H- benzofuro[3a,3,2-ef][2]benzazepínu
US6407229B1 (en) 1994-10-21 2002-06-18 Sanochemia Pharmazeutika Ag Processes for the preparation of derivatives of 4a,5,9,10,11,12-hexahydro-6H-benzofuro-[3a,3,2-ef][2] benzazapine
GB9514821D0 (en) * 1995-07-19 1995-09-20 Sod Conseils Rech Applic Galanthamine derivatives
GB9519268D0 (en) 1995-09-21 1995-11-22 Chiroscience Ltd Preparation of alkaloids
AT403803B (de) 1996-04-19 1998-05-25 Sanochemia Ltd Neue benzazepinderivate, diese enthaltende arzneimittel und verwendung derselben zum herstellen von arzneimitteln
GB9716879D0 (en) * 1997-08-08 1997-10-15 Shire Int Licensing Bv Treatment of attention deficit disorders
AU1430099A (en) * 1998-12-01 2000-06-19 Sanochemia Pharmazeutika Aktiengesellschaft Use of galanthamine and galanthamine derivatives in the case of acute functionalbrain damage
AT414125B (de) 2003-09-29 2006-09-15 Sanochemia Pharmazeutika Ag Neue derivate des 4a,5,9,10,11,12-hexahydro- benzofuro(3a,3,2)(2) benzazepin, verfahren zu deren herstellung sowie deren verwendung zur herstellung von arzneimitteln

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116082352A (zh) * 2023-02-16 2023-05-09 西南交通大学 一种加兰他敏衍生物及其制备方法和用途
CN118908968A (zh) * 2024-10-09 2024-11-08 威胜生物医药(苏州)股份有限公司 一种加兰他敏中间体衍生物及其催化氧化制备方法
CN118908968B (zh) * 2024-10-09 2025-03-04 威胜生物医药(苏州)股份有限公司 一种加兰他敏中间体衍生物及其催化氧化制备方法
CN119528922A (zh) * 2024-11-22 2025-02-28 泰安汉威集团有限公司 一种氢溴酸加兰他敏关键杂质-氢溴酸表加兰他敏的手性合成方法
CN119528922B (zh) * 2024-11-22 2025-12-09 泰安汉威集团有限公司 一种氢溴酸加兰他敏关键杂质-氢溴酸表加兰他敏的手性合成方法

Also Published As

Publication number Publication date
JP2003529602A (ja) 2003-10-07
US20030199493A1 (en) 2003-10-23
AU785385B2 (en) 2007-03-29
SK17022001A3 (sk) 2003-02-04
DE50101827D1 (de) 2004-05-06
NO20015857D0 (no) 2001-11-30
NZ516302A (en) 2004-02-27
PL352638A1 (en) 2003-09-08
SI1181294T1 (en) 2004-08-31
ATE263171T1 (de) 2004-04-15
PL202463B1 (pl) 2009-06-30
SK285909B6 (sk) 2007-10-04
IS2287B (is) 2007-10-15
WO2001074820A1 (de) 2001-10-11
MXPA01012275A (es) 2003-06-24
CZ300160B6 (cs) 2009-02-25
BG65134B1 (bg) 2007-03-30
ES2215885T3 (es) 2004-10-16
EP1181294A1 (de) 2002-02-27
NO326458B1 (no) 2008-12-08
BG106155A (en) 2002-08-30
HK1045990A1 (en) 2002-12-20
TR200400857T4 (tr) 2004-06-21
CZ20014178A3 (cs) 2002-11-13
HUP0202233A3 (en) 2004-12-28
PT1181294E (pt) 2004-07-30
AU4208501A (en) 2001-10-15
NO20015857L (no) 2002-01-29
US7166588B2 (en) 2007-01-23
HK1049832A1 (zh) 2003-05-30
EP1181294B1 (de) 2004-03-31
US20070027138A1 (en) 2007-02-01
DK1181294T3 (da) 2004-08-02
CA2368966A1 (en) 2001-10-11
IS6174A (is) 2001-11-23
RU2241001C2 (ru) 2004-11-27
BR0105563A (pt) 2002-04-02
HUP0202233A2 (hu) 2002-11-28

Similar Documents

Publication Publication Date Title
CN1380883A (zh) 雪花胺的新衍生物和类似物
JP7811578B2 (ja) 中環状または大環状ベンジル置換複素環誘導体およびオレキシン－２受容体アゴニストとしてのそれらの使用
CN105940004B (zh) 化合物
CN104684915B (zh) 新型双环衍生物
CN103201260B (zh) 药物衍生物
JP2023534983A (ja) テトラヒドロピラゾロ－ピラジニル－ジヒドロイミダゾロンまたはテトラヒドロピラゾロ－ピリジニル－ジヒドロイミダゾロン化合物およびそれを使用する方法
CN1069624C (zh) 4a,5,9,10,11,12－六氢－6H－苯并呋喃并[3a,3,2－ef][2]苯并吖庚因衍生物的制备方法
CN1675218A (zh) 新的三环螺哌啶或螺吡咯烷
CN1662506A (zh) 治疗中枢和周围神经系统疾病的方法和组合物及其有用的新化合物
CN101048412A (zh) 哌啶基氨基－噻吩并[2,3－d]嘧啶化合物
CN1882347A (zh) Akt蛋白激酶抑制剂
HK1041698B (zh) 作为阿片受体配体的3-氮杂二环[3‧1‧0]己烷衍生物
CN1922169A (zh) 螺环杂环衍生物及其应用方法
CN1759118A (zh) 作为激酶抑制剂的二氮杂䓬并吲哚衍生物
CN1161334A (zh) 新的取代胍衍生物，其制备方法和其药物用途)
CN1063430C (zh) 乙醇胺衍生物
CN1049219C (zh) 具有内皮素拮抗活性的芳香杂环并环戊烯衍生物
CN1471536A (zh) 趋化因子受体拮抗剂及其使用方法
CN1930160A (zh) Hiv整合酶抑制剂
CN113754654A (zh) 咪唑并吡啶类化合物及其用途
CN101039672A (zh) 化合物
CN1816551A (zh) 吡咯并嘧啶A2b选择性拮抗剂化合物,它们的合成及用途
CN1918160A (zh) 用作趋化因子受体活性调节剂的新颖三环螺环衍生物
CN1335777A (zh) 以NF－κB抑制剂为有效成分的心肌炎、扩张型心肌病和心衰的预防或治疗药
CN1286683A (zh) 四氢苯并吲哚衍生物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1049832

Country of ref document: HK